![]() | |
Clinical data | |
---|---|
Routes of administration | Intravenous,subcutaneous |
ATC code |
|
Pharmacokinetic data | |
Eliminationhalf-life | 2 hours[1] |
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider | |
UNII | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C38H49N9O5 |
Molar mass | 711.868 g·mol−1 |
3D model (JSmol) | |
| |
|
Ipamorelin (INN) (developmental code nameNNC 26-0161) is apeptide selectiveagonist of theghrelin/growth hormone secretagogue receptor (GHS) and agrowth hormone secretagogue.[2][3] It is apentapeptide with theamino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived fromGHRP-1.[4]
Ipamorelin significantly increasesplasmagrowth hormone (GH) levels in both animals and humans.[1][3][5] In addition, ipamorelin stimulates body weight gain in animals.[5] Like pralmorelin andGHRP-6, ipamorelin does not affectprolactin,follicle-stimulating hormone (FSH),luteinizing hormone (LH), orthyroid-stimulating hormone (TSH) levels.[3] However, unlikepralmorelin (GHRP-2) andGHRP-6, but similarly togrowth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion ofadrenocorticotropic hormone (ACTH), orcortisol, and is highly selective for inducing the secretion only of GH.[3]
Ipamorelin was originally developed byNovo Nordisk, and was investigated inphase IIclinical trials byHelsinn Therapeutics for the treatment ofpostoperative ileus, but was discontinued due to lack of efficacy.[6][7]
Ipamorelin has been used by athletes as aperformance enhancing drug.[8][9][10]
![]() | Thishormonal preparation article is astub. You can help Wikipedia byexpanding it. |